Brinton Pharmaceuticals on Thursday reported to received approval from the Drugs Controller General of India to launch Favipiravir 400 mg tablets under the brand name Faviton for Rs 79 per tablet. The tablets are indicated for the treatment of patients with mild to moderate COVID-19 symptoms, Brinton Pharmaceuticals said in a statement.

Under the current treatment regimen with Favipiravir 200 mg tablets, patients have to take 18 tablets on day one, and followed by 8 tablets for next 10-14 days, it added. With the launch of Faviton 400 mg, the number of tablets to be consumed have reduced to half, the statement said.

The tablets will be available across all COVID-19 treatment centres at Rs 79 per tablet, the statement said. "With the launch of Faviton 400mg, the pill burden of the patients will be reduced. It will also offer dosing convenience which will improve the patients' compliance and clinical outcome," Brinton Pharmaceuticals MD Rahul Kumar Darda said.

The company's intent will be to improve the access through its strong distribution network that will help make Faviton 400mg available across all COVID-19 treatment centres, he added.

Brinton is one of the fastest growing Indian Global Pharmaceutical Company spreading its network worldwide.Brinton has a rich and ever-evolving portfolio, state-of-the-art resources in R&D, manufacturing, marketing and sales that assure to deliver value to its customers satisfy unmet medical needs and improve their lives.

Brinton has a tie up with leading manufacturing plants which are certified with all major accreditations such as US FDA, UK MHRA, WHO, GMP, ANBISA - Brazil, Ukraine, Pharmacy and Poison Board Of Kenya, NAFDAC. Nigeria, Ministry of Health Yemen, Ministry of Health Congo, IDA Netherlands & Spanish Agency of Medicines and Health Care Products.